{"disease":{"id":"acc","name":"acc"},"drugs":{"marketed":[{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"abrysvo","indication_name":"Prevention of rabies in individuals who have been bitten or otherwise exposed to rabies or have been at risk of rabies exposure and have been vaccinated with a cell culture vaccine or an inactivated rabies vaccine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrysvo","generic_name":"abrysvo","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":60,"revenue":"1033","mechanism":"ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV)."},{"drug_id":"atorvastatin","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"bosutinib","indication_name":"Accelerated Phase Ph+ CML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosutinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosulif","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"Bosutinib Monohydrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation."},{"drug_id":"elosulfase-alfa","indication_name":"Mucopolysaccharidosis, MPS-IV-A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhgalns","generic_name":"ELOSULFASE ALFA","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"N-acetylgalactosamine-6-sulfatase","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":55,"revenue":"500","mechanism":"VIMIZIM provides exogenous N-acetylgalactosamine-6-sulfatase to increase the catabolism of GAGs KS and C6S in lysosomes."},{"drug_id":"dasatinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"nilotinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"laronidase","indication_name":"Mucopolysaccharidosis, MPS-I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldurazyme","generic_name":"LARONIDASE","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":50,"revenue":"300","mechanism":"Aldurazyme breaks down abnormal sugar molecules in the body to treat Mucopolysaccharidosis I."},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age) (0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adolescents 11 through 12 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adolescents 13 through 18 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for individuals 13 through 18 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adults 19 through 26 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for adults 19 through 26 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adults 27 years of age and older who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for adults 27 years of age and older who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"gleevec","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"simvastatin","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"telmisartan","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"hunterase","indication_name":"Mucopolysaccharidosis type II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hunterase","company_name":"Green Cross Corporation","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quadrivalent-influenza-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in people 6 months of age and older, when the circulating influenza A and B viruses are expected to be well matched to the vaccine viruses.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quadrivalent Influenza Vaccine","company_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","drug_phase":"marketed","molecular_target":"Influenza viruses","drug_class":"Inactivated vaccine","quality_score":34,"revenue":null,"mechanism":"This vaccine works by stimulating the body's immune system to produce antibodies against influenza viruses."},{"drug_id":"aldurazyme","indication_name":"Mucopolysaccharidosis, MPS-I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aldurazyme","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"idursulfase-beta","indication_name":"Mucopolysaccharidosis type II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hunterase","generic_name":"IDURSULFASE BETA","company_name":"Clinigen K.K.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"rosuvastatin","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"pf-07941944","indication_name":"Pf-07941944's indications are not publicly available or I do not have access to the information","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07941944","generic_name":"pf-07941944","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Small molecule","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"vestronidase-alfa","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepsevii","generic_name":"VESTRONIDASE ALFA","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Lysosomal beta Glucuronidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepsevii works by replacing the deficient enzyme beta-glucuronidase in patients with MPS-VII."},{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"idursulfase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elaprase","generic_name":"IDURSULFASE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Elaprase works by replacing the deficient enzyme iduronate-2-sulfatase in the body."},{"drug_id":"ramipril","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altace","generic_name":"RAMIPRIL","company_name":"King Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure."},{"drug_id":"amlodipine","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvasc","generic_name":"amlodipine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"Calcium channel blocker (dihydropyridine)","quality_score":55,"revenue":null,"mechanism":"Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand."},{"drug_id":"pf-07999415","indication_name":"Please note that this information might not be up-to-date or accurate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07999415","generic_name":"pf-07999415","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"vestronidase-alfa-vjbk","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEPSEVII","generic_name":"VESTRONIDASE ALFA-VJBK","company_name":"ULTRAGENYX PHARM INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"pritor","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amlodipin","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amlodipin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tasigna","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mepsevii","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mepsevii","company_name":"Ultragenyx Pharmaceutical Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"imatinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"alteplase","indication_name":"Restoration of function to central venous access devices","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Activase","generic_name":"ALTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"antizol","indication_name":"Accidental poisoning by methyl alcohol","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Antizol","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase, Alcohol dehydrogenase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"licensed-influenza-vaccine","indication_name":"Influenza vaccination","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed influenza vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"vaccine","quality_score":55,"revenue":null,"mechanism":"The mechanism of action is not specified."},{"drug_id":"fomepizole","indication_name":"Accidental poisoning by methyl alcohol","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antizol","generic_name":"FOMEPIZOLE","company_name":"Par Pharm Inc","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase","drug_class":"Antidote [EPC]","quality_score":10,"revenue":null,"mechanism":"Antizol works by competitively inhibiting the enzyme alcohol dehydrogenase, which is responsible for converting toxic alcohols into their more toxic metabolites."},{"drug_id":"elaprase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elaprase","company_name":"Shire","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"edetic-acid","indication_name":"Accidental poisoning by lead and its compounds and fumes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcium Disodium Versenate","generic_name":"EDETIC ACID","company_name":"Medicis","drug_phase":"marketed","molecular_target":"Amyloid beta A4 protein","drug_class":"Anti-coagulant","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dimercaprol","indication_name":"Accidental poisoning by lead and its compounds and fumes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bal","generic_name":"DIMERCAPROL","company_name":"Provepharm Sas","drug_phase":"marketed","molecular_target":"","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"licensed-influenza-vaccine-3","indication_name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed Influenza Vaccine 3","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Influenza virus hemagglutinin protein","drug_class":"Vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"vorapaxar","indication_name":"Cerebrovascular accident","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zontivity","generic_name":"VORAPAXAR","company_name":"Key Therap","drug_phase":"marketed","molecular_target":"Proteinase-activated receptor 1","drug_class":"Protease-activated Receptor-1 Antagonist","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"erdosteine","indication_name":"Accidental poisoning by lead and its compounds and fumes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dithiosteine","generic_name":"ERDOSTEINE","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"erdosteine","quality_score":27,"revenue":null,"mechanism":"Erdosteine works by binding to heavy metals and facilitating their excretion from the body."},{"drug_id":"flu-vaccine","indication_name":"Prevention of influenza caused by virus subtypes A and B contained in the vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flu Vaccine","company_name":"La Fundacion Favaloro para la Investigacion y la Docencia Medica","drug_phase":"marketed","molecular_target":"Influenza A and B viral hemagglutinin and neuraminidase surface antigens","drug_class":"Prophylactic vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older for the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Moderna COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Novavax COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older for the Janssen COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (subcutaneous injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"nicotine-patch","indication_name":"Tobacco Use Cessation","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotine Patch","generic_name":"nicotine-patch","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11","quality_score":null,"revenue":null,"mechanism":"Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11"},{"drug_id":"long-term-varenicline","indication_name":"Tobacco Use Disorder","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Long-Term Varenicline","generic_name":"long-term-varenicline","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Varenicline tablet x 24 weeks","quality_score":null,"revenue":null,"mechanism":"Varenicline tablet x 24 weeks"},{"drug_id":"short-term-varenicline","indication_name":"Tobacco Use Disorder","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Short-Term Varenicline","generic_name":"short-term-varenicline","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t","quality_score":0,"revenue":null,"mechanism":"varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t"},{"drug_id":"0-5mg-varenicline-b-i-d","indication_name":"Tobacco Dependence","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"0.5mg Varenicline b.i.d.","generic_name":"0-5mg-varenicline-b-i-d","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t","quality_score":null,"revenue":null,"mechanism":"Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t"},{"drug_id":"1-0mg-varenicline-b-i-d","indication_name":"Tobacco Dependence","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"1.0mg Varenicline b.i.d.","generic_name":"1-0mg-varenicline-b-i-d","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t","quality_score":null,"revenue":null,"mechanism":"Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t"},{"drug_id":"nitroglycerin","indication_name":"Subcutaneous nitroglycerin to facilitate trans-radial access","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."}],"offLabel":[],"totalMarketed":284,"totalPipeline":6},"trials":{"data":[{"nct_id":"NCT06199934","title":"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19853610,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06442332","title":"Long-term Consequences of Cyclist Injuries","phase":"","overall_status":"COMPLETED","enrollment_count":6491274,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT05126992","title":"EU Secondary Data Post-Authorisation Safety Study of AZD1222","phase":"","overall_status":"COMPLETED","enrollment_count":5321930,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02875327","title":"Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data","phase":"","overall_status":"COMPLETED","enrollment_count":3217145,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04848441","title":"Risk of COVID-19 Infection After Vaccination","phase":"","overall_status":"UNKNOWN","enrollment_count":2000000,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT05993260","title":"Using Text Messages to Boost COVID-19 Vaccine Booking Rate","phase":"NA","overall_status":"COMPLETED","enrollment_count":1825937,"lead_sponsor_name":"The Behavioural Insights Team","has_results":false},{"nct_id":"NCT05234333","title":"COVID-19 Vaccines Associated Malaise","phase":"","overall_status":"COMPLETED","enrollment_count":1534706,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05873751","title":"A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.","phase":"","overall_status":"COMPLETED","enrollment_count":1307378,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04551248","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT07231016","title":"Influenza Vaccination Against Infectious Complications and Mortality in Older Adults With Fractures: a Large-scale Retrospective Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":561566,"lead_sponsor_name":"Taipei Medical University Hospital","has_results":false},{"nct_id":"NCT04480996","title":"Evaluation of Reporting of Road Traffic Accidents With Drugs Responsible for Cognitive Side Effects (ERoADS)","phase":"","overall_status":"UNKNOWN","enrollment_count":500000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05186571","title":"Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05027464","title":"Developing and Testing a COVID-19 Vaccination Acceptance Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":338718,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT04579822","title":"Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy","phase":"","overall_status":"UNKNOWN","enrollment_count":300000,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT04801524","title":"Text-based Reminders to Promote COVID-19 Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":250000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05537441","title":"Precision Vaccine Promotion in Underserved Populations","phase":"NA","overall_status":"COMPLETED","enrollment_count":228831,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04800965","title":"Text-based Interventions to Promote COVID-19 Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05586178","title":"Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":177720,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT03666026","title":"Patient Portal - Flu Reminder Recall","phase":"NA","overall_status":"COMPLETED","enrollment_count":164205,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT05586204","title":"Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up","phase":"NA","overall_status":"COMPLETED","enrollment_count":154977,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06180447","title":"Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Sun Xin","has_results":false},{"nct_id":"NCT05499299","title":"Volatility and Heterogeneity of Vaccine Sentiments Means Continuous Monitoring is Needed When Measuring Message Effectiveness","phase":"NA","overall_status":"COMPLETED","enrollment_count":127000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04576962","title":"County Level Correlates of HPV Vaccine Series Completion Among Children Ages 11-14 Years in Indiana","phase":"","overall_status":"COMPLETED","enrollment_count":122152,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT04323137","title":"Encouraging Flu Vaccination Among High-Risk Patients Identified by ML","phase":"NA","overall_status":"COMPLETED","enrollment_count":117649,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT05225064","title":"Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)","phase":"NA","overall_status":"COMPLETED","enrollment_count":114512,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT06646406","title":"Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate","phase":"NA","overall_status":"COMPLETED","enrollment_count":114165,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06898775","title":"Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":112345,"lead_sponsor_name":"Fundación Vacunar","has_results":false},{"nct_id":"NCT05586165","title":"Effects of Prompt to Bundle COVID-19 Booster and Flu Shot","phase":"NA","overall_status":"COMPLETED","enrollment_count":109493,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT02924467","title":"Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates in New York State","phase":"NA","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06831383","title":"The STOP-HPV Scale Up Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT05766189","title":"Wastewater Surveillance to Boost COVID-19 Vaccine Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"Syracuse University","has_results":false},{"nct_id":"NCT05095844","title":"National Vaccine Adverse Event Reporting Survey and Etiology","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Neuroganics LLC","has_results":false},{"nct_id":"NCT07372950","title":"Kaiser Colorado Flu Nudge","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT06057727","title":"Behavioral Economics to Improve Flu Vaccination Using EHR Nudges","phase":"NA","overall_status":"COMPLETED","enrollment_count":80039,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT03855995","title":"A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa","phase":"","overall_status":"COMPLETED","enrollment_count":77953,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02993965","title":"State Immunization Information Systems to Improve HPV Vaccination Rates","phase":"NA","overall_status":"COMPLETED","enrollment_count":77716,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04198688","title":"Effectiveness of Intensive Smoking Cessation Interventions in Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":77380,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT03294473","title":"Centralized Reminder Recall - Flu RCT2","phase":"NA","overall_status":"COMPLETED","enrollment_count":70190,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06300242","title":"Incentives for Influenza Vaccination","phase":"NA","overall_status":"COMPLETED","enrollment_count":69972,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06603090","title":"Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season","phase":"NA","overall_status":"COMPLETED","enrollment_count":66147,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT06521801","title":"Cardio-Renal Registry","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05012163","title":"Lottery Incentive Nudges to Increase Influenza Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":57581,"lead_sponsor_name":"National Bureau of Economic Research, Inc.","has_results":true},{"nct_id":"NCT02761551","title":"Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates","phase":"NA","overall_status":"COMPLETED","enrollment_count":56549,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT05536674","title":"SMS Reminders to Strengthen Demand for HPV Vaccination in Georgia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":55176,"lead_sponsor_name":"The Behavioural Insights Team","has_results":false},{"nct_id":"NCT03714191","title":"Optimizing the Tobacco Cessation Clinical Decision Support Tool.","phase":"","overall_status":"COMPLETED","enrollment_count":54417,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT02251704","title":"Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":54115,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06238726","title":"Nudging Patients to Increase Shingles Vaccination","phase":"NA","overall_status":"COMPLETED","enrollment_count":50786,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT06148779","title":"Can Digitally Delivered First-line Osteoarthritis Treatment Improve Equal Access to Care","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Joint Academy","has_results":false},{"nct_id":"NCT04584645","title":"A Digital Flu Intervention for People With Cardiovascular Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":49138,"lead_sponsor_name":"Evidation Health","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}